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1. Introduction
Colorectal cancer (CRC) is the third most diagnosed cancer in men, next to prostate and lung
cancer. In women it is the second most diagnosed cancer, next to breast cancer. In a time of
limited resources in health care, there has been considerable debate which imaging modality
offers the best non-invasive examination of colorectal cancer, offering both detection and
characterization. The use of multiple diagnostic modalities is both costly and time-consuming.
Clinical evidence amassed over the last several decades indicates that routine colorectal cancer
(CRC) screening, compared to no screening, detects CRC at an earlier stage, reduces the
incidence of CRC or the progression early CRC through polypectomy, and reduces CRC
mortality.
2. Endoscopy
The first complete examination of the colon using a flexible fiber optic endoscope is reported
by Wolff and Shinya in 1971 [42]. Nowadays colonoscopy is the gold standard for evaluation
of the entire colonic mucosa with therapeutic capability of resecting detected malignancies.
In the last years the colonoscopy is the modality of choice to detect and correct the adenomatous
polyps and colorectal cancer. The diagnosis CRC can be confirmed after biopsy in a known
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malignant pathology and by obtaining more tissue sampling and/or a second opinion from a
consulting pathologist in none diagnostic, highly suspected colon lesion. Besides the role as a
diagnostic tool in CRC, colonoscopy identifies subsequent lesions at the time of surgery, which
is called preoperative endoscopic marking. It is performed through metallic clip placement
and endoscopic tattooing.
The colonoscopic equipment consists of camera and four-way tip controls [43]. The camera
can produce images of high-definition quality. The four way tip controls include (1) exami‐
nation of a found patch to confirm an abnormal growth; (2) insufflating air to dilate the lumen
for mucosal inspection and relieving air after examination, (3) irrigating a suspected region;
(4) suctioning to avoid missing lesions under fluid, and (5) inserting biopsy devices.
The patient must undergo bowel preparation - taking clear liquid diet and ingesting laxative
solutions for colon cleansing the day before examination. Sedation is needed to relieve the
discomfort during the procedure, but it increases the costs. The complication of sedation are
different cardiac disturbances such as hypotension, arrhythmias,oxygen desaturation, and
others. The preparation with purgatives may cause abdominal discomfort, nausea, and other
symptoms. The colonoscopy continues from 30 minutes to an hour. The risk during colono‐
scopy consists in colonic perforation in 0,1 % of cases. Colonoscopy fails to visualize the entire
colon in 10–15% and it may miss up to 10–20% of polyps fewer than 10 mm.
Colonoscopy is golden standard for diagnosing of CRC but there are more symptoms which
could be evaluated and appreciated by endoscopic examination, for example- abdominal pain,
unexplained gastrointestinal bleeding, diarrhea of unexplained origin, chronic inflammatory
bowel disease, etc. It is also the most common interventional modality for polypectomy,
hemostasis, balloon dilation, foreign body removal, palliative treatment of neoplasms, etc.
Colonoscopy could be the best screening option for all none specific underdiagnosed gastro‐
intestinal symptoms.
Colonoscopy removes all detected polyps, regardless of histology type- adenomatous or
hyperplastic. Not all of them must undergo resection. The polyps vary in size and polyps under
5 mm are not detected endoscopic. For detection of polyps smaller than 5 mm the virtual
colonospcopy is the alternative to the conventional colonoscopy.
3. Virtual colonoscopy
Virtual Colonoscopy uses computed tomography (CT) imaging virtual- reality technology for
the purpose of screening the entire colon which is reconstructed from abdominal CT images.
The technique starts after cleansing of the colon with oral laxatives with inflation of air or CO2
introduced through rectal tube [71]. Then abdominal CT images are taken during a single
breath holding with sub mm resolution in axial and transverse directions. The volume model
of the colon is constructed from the spiral CT images. Image segmentation is necessary for the
reconstruction of an accurate colon model [72]. Computer graphics navigate inside the 3D
colon model, the navigation is called fly through model. For validating the detection in the 3D
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colon model, interpretation of the 2D image slices at transverse, sagital and coronal directions
is often included in the procedure.
The virtual colonoscopy achieves higher sensitivity and specificity rates compared to conven‐
tional colonoscopy for detecting polyps, which are 8 mm and larger by the same bowel
preparation, and for polyps larger than 10 mm they have a comparable performance. CTC can
be a potential screening tool to supplement OC for colorectal cancer. CTC is refused to be
included in Medicare coverage because of its radiation risk- in about 50 mAs or 2 rads.
Reducing the radiation could be achieved by decreasing of the mAs level optimization of kVp
value, X-ray flux beam collimation, filtering, etc. The low-mAs strategy will lead to higher
noise in the acquired data which results in steak artifacts. The significant amount of X-ray
radiation exposure and the data noise cannot be disregarded and allowed to the CTC to be a
preferred screening modality.
An alternative method to minimize the radiation is to use magnetic resonance imaging (MRI),
i.e., MR colonography (MRC). However, this MRC has several limitation compared to CTC-
high costs, sensitiveness to motion and other artifacts, and has lower spatial resolution.
Modern CT can reach sub-millimeter spatial resolution and acquire a volumetric image of the
abdomen, detecting polyps which are smaller than 5mm.
There are other reasons responsibe for missing small polyps.
The main reason is due to the partial colon cleansing and air/CO2 inflation and this will not
generate a good interface between the colon wall and the lumen. Others include loss of image
information in post-imaging processing, different anatomical characteristics in the bowel
mucosa, residual fluid or stool covering the polyps. The solution could be virtual or electronic
colon cleansing (ECC) - special type of software programming for virtually cleansing of the
colon. It consists of three main components - (1) fecal tagging, (2) image segmentation for
classifying the tagged image voxels, and (3) post-segmentation operation for cleansing the
colon. ECC works virtually on the residual faecal materials with or without adequate bowel
preparation with purgatives (the so called cathartic-free CTC). The ECC must handle with the
partial volume (PV) effect and with the non-uniformly altered image intensity distribution.
Partial volume (PV) effect is the interface between the colon wall and the fecal materials with
heterogeneously enhanced image intensities. The PV effect blurs the interface over several
image voxels, causing the loss of details about the interface what results in the misdetection
of small polyps. A dual energy scans of a modern CT device or a dual X-ray source scanner is
a new challenging imagining modality. Two volumetric images can be acquired simultane‐
ously at two energy levels. It is expected that the polyps would have different image contrasts
in the two scans and if the contrasts are insufficient for segmenting the image voxels, oral
contrast media may be utilized to increase the density of the polyps. The ECC role in this dual
energy strategy is to segment the colonic materials from multi-spectral CT images. After ECC-
cleansing the colon lumen could be easily inspected for abnormalities and polyps along the
long colon during the fly-through navigation.
Variation among readers with different experience has been noticed. Computer-aided
detection (CAD) can minimize the variation among readers’ assessments. CAD system’s
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disadvantages are many false positives (FPs), such as partial bowel cleansing, image noise,
motion artifacts, colon fold structures, etc. High sensitivity CAD with minimal number of FPs
and development of various texture features and virtual biopsy features remains an innovative
research goal.
 
Figure 1. Endoscopic view of corectal tumor – conventional endoscopy
 
Figure 2. Virtual colonoscopy – a view of pediculaneted polypus and a small carcinoma - CT images.
 
Figure 3. Virtual colonoscopy – a view of pediculaneted polypus and a small carcinoma - a 3-D reconstruction after
software rendering.
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4. Imaging diagnostics in rectal cancer
Staging of rectal cancer is of great importance before the surgical treatment, because staging
predicts the management, prognosis, recurrence and/or metastatic disease risk (13). Staging is
divided into local and distant staging. Local staging points at wall invasion, resection margin
involvement and the nodal status for metastasis and distant staging refers to presence or
absence of metastatic disease. Rectal examination using proctoscopy may be considered as an
important tool for newly diagnosed rectal cancers. Proctoscopy may determine better visual‐
ization, localization and fixity of the tumor, including taking biopsy, which may affects
positively the staging of the rectal cancer.
Nowadays several imaging modalities or combination of these are available for evaluating
preoperative staging of colorectal cancer- computed tomography (CT), magnetic resonance
imaging (MRI), and/or endorectal ultrasonography (EUS). EUS and MRI of the pelvis are used
to appreciate the local dissemination while CT defines systemic dissemination. PET is indi‐
cated when there is clinical, biochemical or radiological suspicion of local recurrence or
systemic disease. Functional imaging such as diffusion weighted MRI imaging (DWI) and CT/
PET are used to distinguish fibrosis from tumor [33].
The T staging accuracy in more advanced cancer is achieved by using MR imaging modality
because MRI can distinguish between mesorectum and mesorectal fascia. The N staging
accuracy is also provided by MRI particularly using superparamagnetic iron oxide particles.
4.1. Endorectal ultrasound
The advancing of imaging technologies has made endoscopic ultrasound a modality of choice
in gastrointestinal diseases, regarding diagnosis, staging and prognosis stratification. These
novel techniques assign excellent to rectal tumors.
Endorectal ultrasound (EUS) is useful in evaluating early rectal cancers (T1 and T2 lesions)
and post transanal surgery. EUS can visualize the rectal wall without distinguishing of
mesorectal fascia, peritumor inflammation, or faeces collections. The accuracy of the T stage
evaluation varies from 60%-90% [45].
In comparison to MRI EUS was found to be highly accurate in early lesions ( for T1 and T2 the
accuracy can reach to 100%), as well as for nodal metastases. For evaluation of metastatic
disease neither MRI nor EUS enable reliable diagnosis.
Besides the misleading lymph node assessment, EUS has its disadvantages in detecting T3
lesions (advanced, stenotic, bulky lesions) or tumors after neoadjuvant therapy, and the
technique is operator dependent.
Hypoechoic appearance, size > 5 mm, round shape, peritumoral location are characteristics
suggestive of malignant involvement of lymph nodes [45,46,51-53]. EUS-guided fine-needle
aspiration can be carried out from the lesion or suspiciously looking lymph nodes.
An newer technique is the three-dimensional ERUS (3D-ERUS). It consists of transverse,
coronal and sagittal scan and has been found to be more reliable in staging colon cancer to
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two-dimensional EUS and CT. The accuracy of 3D-ERUS for assessing the depth of cancer
infiltration and for nodal involvement is with 10% more than the other imaging modalities.
3D images have proved a better visualization of the mesorectal margins. With 3D-ERUS the
surgeon can perform endoscopic mucosal resections of early tumors. A reliable predictor for
response after chemoradiation therapy are the accurate volumetric measurements achieved
by 3D-ERUS. Using Doppler signal enhancers tumor perfusion can be determine, coming to
better results in neoadjuvant therapy and antiangiogenesis treatment.
3D-ERUS, elastography, and contrast enhancement might bring additional information,
increasing diagnostic accuracy of ERUS and amplifying its roles in the complex management
in rectal cancer.
 
Figure 4. Endorectal ultrasonography – a view of T-3 carcinoma - 3-D reconstruction after real-time software render‐
ing.
T and LN staging
In colon cancer patients it is essential to correctly determine the TNM stage. The modalities of
choice are CT, MRI and, as mentioned above, the novel technique ERUS.
ERUS shows high sensitivity and specificity in T-staging and is prior to CT and MRI for staging
superficial rectal tumors, with accuracy in evaluating rectal wall invasion to 97% [23,24]. For
T1, T2, T3 and T4 staging accuracy of ERUS is more than 80%. One common finding is a lower
accuracy for T2 tumors, because the impossibility in distinguishing those tumors that have
deep invasion into the muscularis propria from those with microscopic invasion into the
perirectal fat.
Transanal endoscopic microsurgery (TEM) and endoscopic submucosal dissections are novel
important strategies which directs the mode of surgery because of the ability to visualize the
submucosa. This can lead to down- or upstaging of the detected rectal cancer. Besides ERUS
can detect recurrence at the anastomosis site and to differentiate between postoperative scars
and local recurrences. Unfortunately assessment for nodal metastases is less accurate than that
for tumor depth and reaches 75%. For rectal cancer in particular, over half of the metastatic
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nodes are less than 5 mm and are located within 3 cm of the primary tumor [31]. Metastatic
disease was shown to predict local recurrence.
The sensitivity of ERUS in detecting LN metastasis ranges from 50% to 83%, because small
lymph node (less than 5mm) is not observed with ERUS and it has limited field of view. Factors
for malignancy in lymph node besides node size, echogenicity, shape, border, include:
hypoechogenicity, short axis ≥ 5 mm, long axis length greater than 9 mm.
Detecting of iliac adenopathy is crucial because it goes after total mesorectal excision. This is
possible through flexible not rigid probes. In general, ERUS is better at detecting lymph nodes
in the distal and middle thirds of the rectum [21,33]. The reactive swollen lymph nodes, small
blood vessels, urethra, and seminal vesicle often are mistaken for malignant lymph nodes and
these results in over staging of the disease. On the other hand, the major reason for nodal status
under staging is misdetecting of very small involved nodes (less than 2 mm) and nodes outside
the perirectal tissue [21,33].
Preoperative chemoradiation is a limiting factor affecting accurate staging of rectal cancer.
There are associated reactive and inflammatory changes in the rectum wall after radiotherapy.
However, radiotherapy affects the wall thickness but does not change the five-layered image.
The 3D reconstruction allows improved T and N staging through direct visualization of subtle
protrusions of tumors infiltrating into adjacent tissues and organs.
Limitations of ERUS are several. Firstly it is operator’s experience dependent; it varies after
partial excision or neoadjuvant chemoradiation. It has poor patient acceptability and it has
limited depth of penetration; Another disadvantages are those that it cannot be performed in
obstructive tumors [16,21]; it is unable to visualize tumors located higher with a rigid probe.
It is insufficient in detecting lymph nodes outside the range of the transducer, or visualize
mesorectal fascia because of its limited field of view. In addition, accuracy is affected by villous
or pedunculated tumors, inflammation, hemorrhage [22,31].
MRI
MRI obtain image identification of the distance of the CRM to the tumor, the relation to pelvic
floor and anal sphincter complex, differentiation between mucinous and none mucinous
neoplasia. T staging accuracy of MRI is 52% when compared to histology, because of the
interface between muscularis propria, perirectal fat and mesorectal fascia. MRI cannot
distinguish between T1 and T2 lesions, as well as between T2 and T3 cancer.
T staging
The depth of invasion through the muscle wall is one important element seen on MRI that can
help guide clinical decision making for patients with rectal cancer. Not only does the inci‐
dence of nodal involvement increase with increasing tumor penetration [19,20], but clinical
studies have shown that patients with stage ฀ (T1-2 N0) rectal cancer do not benefit from neo-
adjuvant radiotherapy [21] and may be amenable to a less than radical surgical treatment [22].
Patients with clinically staged T3-4 tumors typically require preoperative CRT since it re‐
duces the rates of local recurrence more effectively than either postoperative CRT or preopera‐
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tive radiotherapy alone [23-25]. However, some problems remain with T stage determination
on MR imaging. Overall, the agreement between MRI and histology for T staging has ranged
from 66%-94% [18,26-28]. One of the main problems of T staging on MRI is the distinction
between T2 and T3 tumors. In fact, investigators have shown that the negative predictive value
for invasion beyond the muscularis propria varied from 93% (expert reading) to 76% (general
radiologist reading) [26]. This difficulty is attributed to the presence of desmoplastic reac‐
tions around the tumor. This reaction makes it difficult to distinguish between spiculation in
the perirectal fat caused by fibrosis alone from that caused by fibrous tissue that contains tumor
cells [26]. In contrast, MRI has been shown to be more accurate in imaging the more advanced
tumors (T4) [27,29]. According to a metaanalysis, MRI for T4 lesions has a specificity of 96% [30].
CRM
The CRM (lateral, radial) is defined as the surgical cut surface of the connective tissues (i.e.
lymphovascular, fatty and neural tissue) that circumferentially encase the rectum. It equates
to the mesorectal fascia that forms the plane of dissection in rectal cancer surgery. It is assessed
Figure 5. Endorectal ultrasonography – a real time 3-D reconstruction with different options for endorectal evaluation
of the tumor process.
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by marking the outer surface (i.e. the CRM) with ink, taking serial cuts through the specimen
and examining the macroscopic and microscopic relations between the tumor and the inked
margin. The CRM gives significant information not only about the quality of the performed
operation but also prognosis of the disease. Indeed, in a recent study based on the data from
a randomized clinical trial, Nagtegaal et al [31] demonstrated in a multivariate model that the
CRM is more important than the T stage for the prognosis of rectal cancer. The definition of a
positive CRM remains a matter of debate. A review of the literature in 2006 showed that the
majority of studies that dealt with CRM status used the ≤ 1 mm definition for positive CRM
(91.1%; 7373 of 8094 patients) [32].
Six distinct types of CRM involvement have been described; direct tumor spread which occurs
in 18% to 29% of cases; discontinuous tumor spread in 14% to 67% of cases; lymph node
metastases in 12% to 14% of cases; venous invasion in 14% to 57% of cases; lymphatic invasion
in 9% of cases; and perineural tumor spread in 7% to 14% of cases [32]. In approximately 30%
of patients, there is more than one type of margin involvement. In contrast to direct tumor
spread, the involvement of the CRM by lymph node metastases is not associated with local
recurrence [32]. MRI is highly accurate and reliable for prediction of the CRM [33,34]. In their
most recent study of 98 rectal cancer patients, Brown et al [27] reported a 92% agreement
between MRI images and histologic findings for prediction of CRM involvement. In another
study assessing the tumor relationship to the mesorectal fascia, two observers independently
scored the tumor stage and the distance to the mesorectal fascia on MRI and compared these
observations with the final histological findings [26]. For twelve tumors with involved
mesorectal fascia, and thus, a CRM of 0 mm, the accuracy in predicting the CRM was 100% for
both readers. In 29 patients with a wide CRM (10 mm), the accuracy for predicting the negative
margin was 97% (27 of 28) for one reader and 93% (26 of 28) for the other [26]. It is relevant to
point out that 5 mm of mesorectal tissue surrounding the lateral tumor edge on MRI was shown
to equal a CRM of 2 mm in the surgical specimen [26]. In the report by Nagtegaal et al [35], a
linear regression curve showed that the crucial distance of at least 2 mm could be predicted
with 97% confidence when the distance on MRI is at least 6 mm. Therefore, the safe rule to
predict CRM involvement on MRI is considered to be an MRI measurement minus 4 mm due
to shrinkage of the specimen with fixation [6]. Of note, the CRM becomes more difficult to
identify in low, anterior tumors and in patients with a limited amount of perirectal fat [36]. In
a recent study by Frasson et al [37], the 5-year local recurrence rates for patients with a
preoperative CRM of < 2 mm on MRI or EUS who did not receive preoperative chemoradiation
was 19.4% compared to 5.4% for patients with a non-threatened margin. It is important to
realize that a short course of preoperative radiotherapy has limited ability to control positive
CRM. An analysis of more than 17 500 pathologic specimens by Nagtegaal et al [32] revealed
that the chance of local recurrence was higher for patients with a positive CRM after neoad‐
juvant treatment (both radiotherapy and radiochemotherapy) than those with a positive CRM
following immediate surgery (Hazard ratio 6.3 vs 2.0, respectively). Similar results have been
reported following postoperative treatment [38]. In the MRC CR-07 trial, patients with positive
radial margins who were selected to receive postoperative chemoradiation had a 21% local
recurrence rate [39]. Thus, in cases where the tumors are close (< 2 mm) or through the
mesorectal margin on preoperative MRI, a more aggressive treatment regimen is required with
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neoadjuvant CRT or an upfront regimen of chemotherapy before chemoradiation prior to
operation. In contrast, patients with a free margin > 2 mm from mesorectal fascia may undergo
surgery [total mesorectal excision (TME)] alone, avoiding preoperative chemoradiation.
Interestingly, MRI-based therapy for CRM positive tumors was able to reduce the frequency
of neoadjuvant therapy for rectal carcinoma by 35% without the risk of worsening the
oncological results [40]. However, omitting preoperative chemoradiation for all CRM-negative
tumors on MRI needs to be further investigated in prospective clinical trials before it is adopted
as standard therapy.
N staging
The presence of involved lymph nodes is an indicator for the likelihood of systemic disease
and local recurrence [41]. Therefore node-positive disease is generally an indication for
preoperative chemoradiation. However, radiological evaluation of lymph node metastatic
involvement remains a challenge. Results of anatomic studies show that over half of the
metastatic nodes from rectal cancer are within 3 cm of the primary tumor and are smaller than
5 mm in size [42]. With a standard TME, the perirectal nodes are removed with the primary
tumor, but the internal iliac and obturator nodes are left in place. Moriya et al [43] reported
that as many as 28% of lymph node-positive distal rectal cancers have involvement of lateral
nodes and in 6% of cases, these were the only nodes involved. This means that in 6% of patients,
the disease was incorrectly staged postoperatively as node-negative at TME. For pre-operative
lymph node imaging, MRI at present is only moderately accurate, although this could change
with advances in new MR techniques. Currently, the reported accuracy rate of MRI for nodal
staging ranges from 71% to 91% [42]. On MRI, lymph nodes typically have lower signal
intensity than the perirectal fat but higher signal intensity than arteries and veins. In patients
with mucinous carcinoma, metastatic lymph nodes are visualized as hyperintense nodules
alone or as hyperintense areas within hypointense nodules. A node is considered enlarged if
the major axis length is more than 5 mm (mesorectal), 7 mm (internal iliac), 10 mm (external
iliac), or 9 mm (common iliac) [44]. However, the morphological features or signal intensity of
the nodes on MRI may more accurately determine metastatic involvement rather than
measurement of size. Brown et al [45] demonstrated that an irregular border or mixed signal
intensity of lymph nodes on MRI improved the specificity of predicting nodal status from 68%
(based on size alone) to 97%. One of the more promising advances of MRI may be the use of
new lymphographic agents that help assess tumor spread to lymph nodes. In a recent study,
gadofosveset-enhanced MRI improved the specificity of nodal staging from 82% achieved with
standard MRI to 97% [46]. Fusion of diffusion-weighted MR with T2-weighted images
improves identification of pelvic lymph nodes compared with T2-weighted images alone.
Using fusion images, 29% additional nodes were detected compared with T2-weighted images
alone [47]. The improved nodal identification may aid in treatment planning.
For the vast majority of rectal carcinomas, MRI is currently the most accurate modality on
which to base treatment decisions for patients with rectal cancer. Traditionally, the decision
to apply preoperative treatment for rectal cancer patients has been based on the T- and N-
stage. Lately, other MRI findings such as the radial distance of the tumor to the CRM and
extramural vascular invasion score have been identified as important risk factors for local
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failure and survival. Every center that treats patients with rectal cancer should develop a
multidisciplinary team featuring a description of the MRI findings and their implementation
in the treatment strategy with the aim of increasing resectability, reducing the local recurrence
and treatment morbidity, and improving the quality of life.
 
Figure 6. MRI – a view of T-3 carcinoma - 3-D reconstruction after real-time software rendering.
CT, MRI and intraoperative ultrasound for evaluation of the systematic progression in
colorectal cancer
The morbidity rate for patients with cancer depends on the early detection of liver metastases.
The presence of liver metastases makes of the primary tumour non-resectable for oncologic
reasons, except for tumour palliative treatment (for example resection for obstruction of the
gastrointestinal tract). For a few malignancies, as in colorectal carcinoma, resection of liver
metastases has been shown to improve the survival of the patients. The hepatic metastases are
divided into synchronous (i.e. occurring at the time of diagnosis of the primary tumour) and
metachronous (occurring after diagnosis of the primary tumour). The surgical resection of the
metastases depends on the division, number, size, regional distribution and all clinical
parameters of the patient, which makes resectable only 30% of all colorectal patients with
metastases. The 5-year survival rate of these patients is more than 30% in comparison to a
survival of less than 5% of patients with liver metastases not amenable to liver surgery [1–4].
The goal of imaging modalities is to assess the presence or absence of liver metastases in
surgical candidates. Different studies indicate ferumoxide-enhanced magnetic resonance (MR)
imaging as more sensitive and specific than contrast-enhanced computed tomography (CT) in
detection of hepatic metastases. The different MR pulse sequences and MR contrast media
agents makes MRI the modality of choice for non-invasive lesion characterization.
Preoperative assessment of surgical candidates
Preoperative assessment of metastatic liver involvement should be performed for all surgery
candidates. This preoperative staging is conceivable by contrast-enhanced CT and/or MRI in
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most oncologic centers. All imaging modalities present different false-positive or false-
negative diagnoses- for helical CT- in 42%, intraoperative US- in 22.8%, mangafodipir-
enhanced MRI- in 10%, ferumoxide-enhanced MRI technique is accurate as CT during
arterioportography (CTAP)- in 19%. Another study found that FDG-PET CT is the most
sensitive method for detection of metastases. There is no firm statement which is the best
imaging modality, further more the choice depends on local equipment, availability, and
operator expertise. MDCT is preferred as a screening method for hepatic lesions because of its
ability to reduce respiration-related artifacts, to shorten scan time, to perform multiphase
scanning. The disadvantage is the high radiation exposure.
Clinical Role of Intraoperative US
Intraoperative US provide more diagnostic and staging information to the surgeon during
hepatic resection. Intraoperative US supplies 35% more information about the lesion type,
localization and expansion to adjacent tissues, relation to vascular structures, providing more
specificity in the evaluation of liver lesions. In addition intraoperative US represent 25% more
lesions than did preoperative US, CT, or angiography. This results in correction in disease
staging, which affects the surgical management and postoperative treatment. The intraoper‐
ative US has a positive effect on patient care, surgical planning, and clinical outcome.
Magnetic resonance imaging
The standard phased array MRI produces good quality images with good contrast resolution
and a relatively large field of view, so it is the modality of choice for preoperative staging of
rectal primary tumor. MRI is reliable for assessment of the tumor and its locoregional exten‐
sion, for identifying recurrence and for planning radiation therapy. The disadvantage of MRI
is impossibility in evaluation nodal metastases.
Figure 7. Intraoperative ultrasound of the liver
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Deciding in management of rectal cancer is the differentiation of the mesorectal fascia-
circumstance, which is possible using phased-array coils (confirmed from the multicentre
European MERCURY study)(21,23).
MRI may not be the examination of choice for every patient. Patients with contraindications
to MRI (e.g. implantable pacemakers), or unable to tolerate MRI (e.g. due to claustrophobia)
would preferably undergo preoperative imaging with CT. Motion related imaging artifacts
that can severely dampen the diagnostic quality of MRI will occur in patients who are unable
to breath hold for longer than 20 seconds.
FDG PET in the Initial Staging of CRC
FDG PET is not a routine investigation for primary cancer due to its limited spatial resolution.
PET cannot define the T-category of the primary tumor, but PET is superior to other imaging
modalities in detecting of lymph node and distant metastases- an important prognostic factor.
After PET-CT investigation the patient could be upstaged in 17% because of identifying
unsuspected systemic and lymph node metastases. But the specificity of PET in nodal staging
does not be higher than multi-detector CT scan (MDCT).
The  principle  of  positron  emission  tomography (PET)  (and Fluoro-deoxy-glucose  (FDG)
used as tracer or enhancer) is based on the differential metabolic profile of tumors - higher
metabolic activity, change in the tumor biology. FDG/PET is mainly useful in the assess‐
ment of local recurrence and metastases.  Besides in neoplastic cells FDG accumulates in
areas of inflammation, infection,  in organs of increased metabolic activity such as brain,
myocardium, liver or kidneys leading to false positive results. Interpretation of PET without
anatomic correlation is difficult which results in necessity of fusing PET with CT images-
PET-CT fusion scans are invented. This offers a detailed anatomical and functional imaging.
The combination provides additional value to localize the hot spots. The false positive rates
are  due  to  other  diseases  and physiological  processes.  PET scans  improve  the  manage‐
ment plan for rectal cancer. The addition of FDG-PET changes patient management in up
to  30%  of  patients  with  potentially  resectable  liver  metastases,  mainly  by  detecting
previously unknown extrahepatic disease. Furthermore, FDG-PET is useful in the follow-
up  of  patients  who  underwent  surgical  procedures  of  the  liver,  since  it  is  sensitive  in
detecting residual or relapse malignancy in scarred liver tissue following both resection and
local ablative techniques. For follow-up during systemic therapy, early FDG-PET appears
predictive  for  response  to  therapy.  FDG-PET,  computerized  tomography  and  magnetic
resonance imaging are complementary techniques in staging and restaging patients with
advanced colorectal  cancer.  A combination of  FDG-PET and CT scanning characteristics
seems promising, and integrated PET/ CT is becoming more widely available, although the
exact clinical value and efficacy is not yet fully established. In addition, assessment of these
modalities in joint reading sessions with radiologist, nuclear medicine physician, medical
and  surgical  oncologists  significantly  impacts  upon  patient  management.  This  review
evaluates the potential of FDG-PET and combined PET/CT in patients with colorectal liver
metastases and discusses potential future possibilities.
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Suggested investigations for tumor staging of rectal cancer
CT scanning is still the current standard for distant staging, but not to stage the local neoplasm.
The combination of CT and PET offers both anatomical and functional imaging, so it is
sufficient for recurrent rectal cancers. MRI and EUS should be considered as the initial
modalities to stage the local tumor. For T1-T2 lesions EUS is more appropriate, whereas MRI
is used in advanced rectal cancer. MRI has been shown to be highly accurate in predicting a
clear circumferential resection margin in patients undergoing TME.
Suggested investigation for nodal staging of rectal cancer
Significant malignant lymph nodes (more than 1cm in diameter), in conjunction with size,
shape and morphology, are identified through MRI, CT and EUS studies. The enlarged lymph
node can be as a result of the inflammatory process but normal size nodes can have microme‐
tastases. Moreover the halves of nodes less than 5 mm are proved to be malignant. One novel
technique involves use of a contrast media containing superparamagnetic iron oxide particles
SPIO which accumulates in normal lymph nodes, but not in malignant nodes due to poor
uptake. Then, using T2 weighted imaging, these nodes can be identified. Initial studies are
promising but further research is needed [35].
Figure 8. Positron emission tomography of the liver – an observation of metastasis from colorectal origin
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 Figure 9. Positron emission tomography of the body – an observation of perirectal lymphadenopathy
5. Conclusion
Optical colonoscopy (OC) and virtual colonoscopy (VC) (i.e. CT colonoscopy and MR colono‐
scopy) are constantly developing and adapting to the new clinical needs. The optical colono‐
scopy has the advantage of being both diagnostic and therapeutic procedure for patients with
positive findings on screening tests. The virtual colonoscopy is much less invasive method and
can be used for mass screening because of the high prevalence of the colorectal cancer. As a
screening test the VC has advantages over OC and other options such as FOBT, FIT, stool DNA
testing, and DCBE. These methods can make a good combination of VC screening with OC
follow-up on the positive findings. The current imaging modalities for VC are CT and MRI
and in the future other modalities might be available.
The imaging standard for accurate diagnostics for colorectal cancer includes ultrasound (US),
CT and MRI. The nuclear medicine has its role in finding extra-regional localization of the main
disease by FDG-PET and FDG-PET/CT. The protocol for liver metastases includes CT as a first
choice, which is followed by US. Lung-metastases are evaluated by X-ray or chest CT. The
extrahepatic metastases are assessed by CT. The present guidelines could be adjusted by
conducting comparative studies on different strategies for colon and rectal cancer, such as CT
liver/abdomen vs. MRI liver/abdomen for liver and extrahepatic metastases, X-ray chest and
CT chest for lung metastases.
The screening of asymptomatic patients is justified due to the high prevalence of colon
carcinoma and the mortality can be effectively reduced by removing adenomatous polyps.
Although effective, this method consumes large resources if applied to the whole target
population. The currently available screening options have limitations. The VC has the option
to identify patients with adenomatous polyps. The combination of VC screening and OC
follow-up might prove as a cost-effective measure against colorectal cancer.
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The challenges of VC are the associated radiation and the differentiation of the colonic
materials from the colon wall. The MRI-based VC has no radiation and has better potential in
differentiation of colonic materials from the colonic wall, but it has lower spatial resolution
and is prone to motion artifacts. CT and MRI VC require sophisticated software processing to
construct the colon model and real-time fly-through inside the lumen. More sophisticated
image processing is important for the differentiation of adenomatous from hyperplastic ones.
The extraction of the colon wall can be performed by the new method of electronic colon
cleansing and analysis of texture features from image intensity of the wall. These processing
methods are step toward computer-aided detection and diagnosis. Despite recent advances in
chemotherapeutic agents, the prognosis for metastatic colon cancer remains poor. Over the
past two decades, hepatic metastasectomy has emerged as a promising technique for improv‐
ing survival in patients with metastatic colon cancer and in some cases providing long-term
cure. To maximize safety and efficacy of metastasectomy, appropriate pre-operative imaging
is needed. Advancements in computed tomography (CT), magnetic resonance imaging (MRI)
and positron emission tomography (PET) have led to improved detection of occult lesions and
better definition of surgical anatomy. While CT, PET and MRI have a comparable sensitivity
for detection of large liver metastases, MRI excels at detection of subcentimeter liver metastases
compared to CT and FDG-PET, especially with the combination of diffusion weighted imaging
(DWI) and hepatocyte-specific contrast agents. CT may be useful as a screening modality or
in preoperative planning such as volumetric estimation of the remnant liver size or in defining
preoperative arterial anatomy for hepatic artery infusion pump placement. While technologic
advancements have led to unprecedented image quality and clarity, this does not replace the
need for a dedicated, competent radiologist with experience in hepatic imaging.
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